NASDAQ:ABCM Abcam (ABCM) Stock Forecast, Price & News $22.55 -0.04 (-0.18%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$22.55▼$22.6550-Day Range$21.54▼$23.8952-Week Range$12.48▼$25.32Volume10.46 million shsAverage Volume10.55 million shsMarket Capitalization$5.17 billionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Abcam MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside2.0% Upside$23.00 Price TargetShort InterestHealthy0.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.20Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth29.55%From $0.44 to $0.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector666th out of 965 stocksBiological Products, Except Diagnostic Industry108th out of 160 stocks 1.1 Analyst's Opinion Consensus RatingAbcam has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Abcam has a forecasted upside of 2.0% from its current price of $22.55.Amount of Analyst CoverageAbcam has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.78% of the outstanding shares of Abcam have been sold short.Short Interest Ratio / Days to CoverAbcam has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abcam has recently decreased by 5.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbcam does not currently pay a dividend.Dividend GrowthAbcam does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCM. Previous Next 3.4 News and Social Media Coverage News SentimentAbcam has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Abcam this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ABCM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows9 people have added Abcam to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abcam insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.73% of the stock of Abcam is held by insiders.Percentage Held by Institutions90.45% of the stock of Abcam is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Abcam are expected to grow by 29.55% in the coming year, from $0.44 to $0.57 per share.Price to Earnings Growth RatioAbcam has a PEG Ratio of 2.06. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbcam has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Abcam (NASDAQ:ABCM) StockAbcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.Read More ABCM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCM Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comAbcam (NASDAQ:ABCM) Sees Unusually-High Trading VolumeSeptember 21, 2023 | finance.yahoo.comHeadwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – ExclusiveSeptember 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 19, 2023 | americanbankingnews.comShort Interest in Abcam plc (NASDAQ:ABCM) Drops By 5.3%September 17, 2023 | americanbankingnews.comAbcam (NASDAQ:ABCM) Sees Strong Trading VolumeSeptember 15, 2023 | msn.comAbcam holder, founder Jonathan Milner opposes Danaher acquisition (update)September 14, 2023 | benzinga.comAbcam plc Statement on Dr. Jonathan Milner's AnnouncementSeptember 14, 2023 | msn.comAbcam holder, founder Jonathan Milner opposes Danaher acquisitionSeptember 24, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.August 31, 2023 | finance.yahoo.comAbcam plc Interim Results for the Six-Month Period Ended 30 June 2023August 30, 2023 | msn.comAbcam cut to market perform at Leerink, sees no antitrust riskAugust 29, 2023 | msn.comAbcam deal price may have been hurt by antitrust concerns - report (update)August 29, 2023 | benzinga.comABCAM INVESTOR ALERT by the Former Attorney...August 29, 2023 | markets.businessinsider.comBank of America Securities Remains a Buy on Abcam (ABCM)August 28, 2023 | msn.comDanaher Buys Abcam for $5.7 Billion to Expand Its Product OfferingsAugust 28, 2023 | technews.tmcnet.comABCM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Abcam plc Is Fair to ShareholdersAugust 28, 2023 | msn.comDanaher Buying UK-Based Abcam in $5.7 Billion All-Cash DealAugust 28, 2023 | msn.comAbcam deal price may have been hurt by antitrust concerns - reportAugust 25, 2023 | msn.comAbcam gains on reports Danaher in lead to acquire companyAugust 6, 2023 | fool.comAbcam Plc (NASDAQ: ABCM)July 31, 2023 | finance.yahoo.comHere’s Why Abcam plc (ABCM) Outperformed in Q2July 25, 2023 | finance.yahoo.comAre Medical Stocks Lagging Abcam (ABCM) This Year?July 25, 2023 | finance.yahoo.comAre Medical Stocks Lagging Abcam (ABCM) This Year?July 12, 2023 | finance.yahoo.comAbcam plc: All Resolutions Withdrawn at Abcam's EGMJuly 6, 2023 | theglobeandmail.comInstrument Name Abcam Plc ADR Instrument Symbol (ABCM-Q)June 28, 2023 | finance.yahoo.comAbcam Confirms Dr. Jonathan Milner has Withdrawn EGM Requisition Notice and Related ResolutionsJune 27, 2023 | msn.comAbcam Provides FY24 Guidance & Confirms FY23 OutlookSee More Headlines Receive ABCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCM Company Calendar Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABCM CUSIPN/A CIK1492074 Webwww.abcam.com Phone44-0-12-2369-6000FaxN/AEmployees1,760Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$23.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+2.0%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio51.25 P/E Growth2.06Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.00 Sales & Book Value Annual Sales$447.49 million Price / Sales11.55 Cash Flow$0.60 per share Price / Cash Flow37.79 Book Value$3.92 per share Price / Book5.75Miscellaneous Outstanding Shares229,270,000Free Float213,842,000Market Cap$5.17 billion OptionableNot Optionable Beta0.93 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Alan Thomas Hirzel BS (Age 55)M.B.A., M.S., MBA, MS, CEO & Exec. Director Comp: $1.19MMr. Michael Shaun Baldock B.A. (Age 59)CFO & Director Comp: $884.64kMarc Leigh Russell PerkinsGen. Counsel & Company Sec.Emma SceatsSr. VP of Sales & MarketingMr. Nick SkinnerSr. VP of HRMs. Alejandra Solache Ph.D.Sr. VP of R&DMr. John BakerSr. VP of Supply Chain & ManufacturingJuan Carlos SacristanSr. VP of Data & DigitalMore ExecutivesKey CompetitorsHalozyme TherapeuticsNASDAQ:HALOVaxcyteNASDAQ:PCVXGinkgo BioworksNYSE:DNACRISPR TherapeuticsNASDAQ:CRSPExelixisNASDAQ:EXELView All CompetitorsInstitutional OwnershipBarclays PLCBought 197,735 shares on 9/21/2023Ownership: 0.090%Brown Shipley& Co LtdBought 128,350 shares on 8/25/2023Ownership: 0.056%Yarbrough Capital LLCBought 20,594 shares on 8/25/2023Ownership: 0.009%Alberta Investment Management CorpSold 96,427 shares on 8/24/2023Ownership: 0.044%Osaic Holdings Inc.Bought 6,337 shares on 8/21/2023Ownership: 0.007%View All Institutional Transactions ABCM Stock - Frequently Asked Questions Should I buy or sell Abcam stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares. View ABCM analyst ratings or view top-rated stocks. What is Abcam's stock price forecast for 2023? 6 analysts have issued 1 year price targets for Abcam's stock. Their ABCM share price forecasts range from $23.00 to $23.00. On average, they predict the company's share price to reach $23.00 in the next year. This suggests a possible upside of 2.0% from the stock's current price. View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts. How have ABCM shares performed in 2023? Abcam's stock was trading at $15.56 at the start of the year. Since then, ABCM shares have increased by 44.9% and is now trading at $22.55. View the best growth stocks for 2023 here. Are investors shorting Abcam? Abcam saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,790,000 shares, a decrease of 5.3% from the August 15th total of 1,890,000 shares. Based on an average daily trading volume, of 4,320,000 shares, the short-interest ratio is currently 0.4 days. View Abcam's Short Interest. What ETFs hold Abcam's stock? ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).ProShares Ultra Nasdaq Biotechnology (BIB). What guidance has Abcam issued on next quarter's earnings? Abcam updated its earnings guidance on Tuesday, June, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $525.50 million-$550.53 million. When did Abcam IPO? (ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at a price of $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO. What is Abcam's stock symbol? Abcam trades on the NASDAQ under the ticker symbol "ABCM." Who are Abcam's major shareholders? Abcam's stock is owned by many different institutional and retail investors. Top institutional shareholders include Durable Capital Partners LP (6.27%), Harding Loevner LP (4.66%), Brown Capital Management LLC (4.34%), Baillie Gifford & Co. (3.56%), Brown Advisory Inc. (2.84%) and Bank of New York Mellon Corp (2.27%). How do I buy shares of Abcam? Shares of ABCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Abcam's stock price today? One share of ABCM stock can currently be purchased for approximately $22.55. How much money does Abcam make? Abcam (NASDAQ:ABCM) has a market capitalization of $5.17 billion and generates $447.49 million in revenue each year. How many employees does Abcam have? The company employs 1,760 workers across the globe. How can I contact Abcam? The official website for the company is www.abcam.com. The company can be reached via phone at 44-0-12-2369-6000 or via email at investor.relations@abcam.com. This page (NASDAQ:ABCM) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.